Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
Wall Street's M&A Chatter From Nov. 20: Marvell Technology, Aetna, Bloomin' Brands, AT&T
Lightning Round: Jim Cramer Weighs In On Wendys, Aetna And More
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2017 Update (Seeking Alpha)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Nov 2017Raymond JamesUpgradesMarket PerformOutperform
Nov 2017Credit SuisseInitiates Coverage OnNeutral
Nov 2017CitigroupMaintainsBuy

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

View Comments and Join the Discussion!

Partner Center